The wet form of age-related macular degeneration (AMD) is currently treated with eye drugs that are blockbuster sellers. Opthea Limited is developing a wet AMD drug that goes after different targets and the biotech struck a pair of financing deals that provide it with the cash for pivotal tests that could show how well its approach works.
David Mayer (@djmventure), who has worked as a Boston-based partner with healthcare and life science venture capital firm Abingworth, is starting his own health IT investment business. Mayer Investors is scheduled to go live March 1. The healthcare investor will target technology-enabled services providers developing cloud-based solutions for healthcare payer, provider, life sciences and consumer […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.